Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Thin Film Freezing Shows Efficacy for Biodefense Countermeasures Against Alphaviruses and Filoviruses

by Global Biodefense Staff
February 19, 2021
Thin Film Freezing Shows Efficacy for Biodefense Countermeasures Against Alphaviruses and Filoviruses

Concept photo of Ebola virus particles and aerosolized droplets.

TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented thin-film freeze-drying (TFFD) technology platform, today announced positive preclinical in vitro efficacy data from TFF formulated biodefense countermeasures.

The data was collected in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) as part of a 3-year Cooperative Research and Development Agreement (CRADA) initiated in April 2020 to investigate TFFD of various biodefense countermeasures to demonstrate the use of these formulations as needle-free, inhaled treatments that are temperature-insensitive.

The first two countermeasures, a monoclonal antibody (mAb) against Ebolavirus Zaire (EBOV) and a recombinant vesicular stomatitis virus (rVSV) vaccine candidate against Venezuelan equine encephalitis virus (VEEV), were TFFD formulated and tested for efficacy in a well-established in vitro neutralization assay. Data showed that the activity of the mAb and rVSV vaccines were preserved after TFFD. Formulation optimization and long-term stability testing are ongoing. Next steps will include in vivo testing in appropriate animal models.

“This data utilizing our TFFD technology to reformulate currently developed and characterized medical countermeasures against EBOV and VEEV is an important milestone,” said Glenn Mattes, CEO of TFF Pharmaceuticals. “Most countermeasures are parenterally delivered, require trained personnel for administration and are temperature sensitive. There is an urgent need to develop technologies to improve biodefense countermeasures to better protect the warfighter.”

“Great strides have been made to develop licensed countermeasures against Department of Defense (DoD) select agents of interest, such as Ebolavirus Zaire (EBOV) and Venezuelan equine encephalitis (VEEV),” said John M. Dye, Jr., Viral Immunology branch chief, USAMRIID. “An alternate route of administration that bypasses the need for cold chain control and administration by specialized personnel could be critical in the protection of our defense forces in biologically hostile environments around the globe.”

TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments, the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.

Tags: AlphavirusDrug DevelopmentEbolaEditor PickImmune ResponseSelect AgentsUSAMRIIDVenezuelan Equine Encephalitis

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy